Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹126.00 Cr |
| Fresh Issue | ₹126.00 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹120.00-126.00 per share |
| BSE Code | 544502 |
| NSE Code | AMANTA |
| Registrar | MUFG Intime India Pvt.Ltd. |
| Lead Managers | Beeline Capital Advisors Pvt.Ltd. |
| Allotment Status |
| DRHP |
| RHP |
| Final Prospectus |
| Anchor List |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 119 shares and in multiples thereof
Incorporated in December 1994, Amanta Healthcare Limited is a pharmaceutical company that specializes in the development, manufacturing, and marketing of a diverse array of sterile liquid products, specifically parenteral products, which are packaged in plastic containers utilizing Aseptic Blow-Fill-Seal (“ABFS”) and Injection Stretch Blow Moulding (“ISBM”) technologies. The company is also a manufacturer of medical devices.
The company manufactures fluid therapy formulations, including IV fluids, diluents, ophthalmic solutions, and respiratory care products. It also offers irrigation solutions, first-aid products, and eye lubricants in the medical device segment.
The company manufactures over 45 generic products, marketing them under their brands in India through 320 distributors and stockists.
The company sells products in Africa, Latin America, the UK, and beyond. Its products are registered in 19 countries and comply with various regulations. In Fiscal 2025, the company exported branded products to 21 countries.
Experienced management team supported by a large, diverse and skilled workforce.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat | 70.00 |
| 2 | Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat | 30.13 |
| 3 | General corporate purposes | 6.60 |
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 381.76 | 352.12 | 374.06 |
| Total Income | 276.09 | 281.61 | 262.70 |
| Profit After Tax | 10.50 | 3.63 | -2.11 |
| EBITDA | 61.05 | 58.76 | 56.31 |
| NET Worth | 96.39 | 66.29 | 62.88 |
| Reserves and Surplus | 67.56 | 39.46 | 36.05 |
| Total Borrowing | 195.00 | 205.23 | 215.66 |
| Amount in ₹ Crore | |||
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 12.42% |
| ROCE | 13.72% |
| Debt / Equity | 2.02% |
| RoNW | 10.89% |
| PAT Margin | 3.86% |
| EBITDA Margin | 22.11% |
| Price to Book Value | 3.77 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 3.64 | 2.70 |
| P/E (x) | 34.59 | 46.59 |
| Promoter Holding | 85.6% | 63.56% |
| Market Cap | ₹489.25 Cr. | |
